| PATENT NUMBER | This data is not available for free |
| PATENT GRANT DATE | October 8, 2002 |
| PATENT TITLE |
Pharmaceutical composition for preventing and/or curing digestive disorders |
| PATENT ABSTRACT | The invention provides a pharmaceutical composition for preventing and/or curing digestive disorders such as digestive ulcers, gastritis, etc. The pharmaceutical composition contains, as the active ingredient, an aluminosilicate having silver and zinc ions, and it has an excellent effect for protecting gastric mucous membrane and an excellent effect of promoting the curing of a gastric ulcer |
| PATENT INVENTORS | This data is not available for free |
| PATENT ASSIGNEE | This data is not available for free |
| PATENT FILE DATE | July 30, 2001 |
| PATENT FOREIGN APPLICATION PRIORITY DATA | This data is not available for free |
| PATENT PARENT CASE TEXT | This data is not available for free |
| PATENT CLAIMS |
What is claimed is: 1. A method of treating digestive disorders selected from the group consisting of an esophageal ulcer, a duodenal ulcer, esophagitis gastritis, enteritis and enterogastric intestinal hemorrage, comprising the step of administering orally to a mammal in need thereof a composition comprising an effective amount of an aluminosilicate having silver and zinc ions. 2. The method as claimed in claim 1, wherein the aluminosilicate is zeolite. 3. The method as claimed in claim 1, wherein said digestive disorders are selected from the group consisting of an esophageal ulcer, a gastric ulcer, a duodenal ulcer and gastritis. 4. The method as claimed in claim 2, wherein said digestive disorders are digestive ulcers or gastritis. 5. The method as claimed in claim 1, wherein said mammal is a human subject. 6. The method as claimed in claim 2, wherein said mammal is a human subject. 7. The method as claimed in claim 1, wherein the aluminosilicate has an average particle size between 0.5 .mu.m and 20 .mu.m. 8. The method as claimed in claim 2, wherein the zeolite has an average particle size between 0.5 .mu.m and 20 .mu.m. 9. The method as claimed in claim 1, wherein the silver ion content in the aluminosilicate is from 0.3% to 40% and the zinc ion content is from 1% to 15% as measured by the weight percentage of silver and zinc, respectively, in the aluminosilicate dried at 110.degree.C. 10. The method as claimed in claim 2, wherein the silver ion content in the zeolite is from 0.3% to 40% and the zinc ion content is from 1% to 15% as measured by the weight percentage of silver and zinc, respectively, in the aluminosilicate dried at 110.degree.C. 11. The method as claimed in claim 1, wherein the aluminosilicate having silver and zinc ions is administered at a dosage between 100 mg/day/adult and 10,000 mg/day/adult. 12. The method as claimed in claim 2, wherein the zeolite having silver and zinc ions is administered at a dosage between 100 mg/day/adult and 10,000 mg/day/adult. 13. A method of protecting the gastric mucous membrane of a mammal, comprising the step of administering orally to a mammal in need thereof a composition comprising an effective amount of an aluminosilicate having silver and zinc ions. 14. The method as claimed in claim 13, wherein the aluminosilicate is zeolite. 15. The method as claimed in claim 13, wherein said mammal is a human subject. 16. The method as claimed in claim 14, wherein said mammal is a human subject. 17. The method as claimed in claim 13, wherein the aluminosilicate has an average particle size between 0.5 .mu.m and 20 .mu.m. 18. The method as claimed in claim 14, wherein the zeolite has an average particle size between 0.5 .mu.m and 20 .mu.m. 19. The method as claimed in claim 13, wherein the silver ion content in the aluminosilicate is from 0.3% to 40% and the zinc ion content is from 1% to 15% as measured by the weight percentage of silver and zinc, respectively, in the aluminosilicate dried at 110.degree.C. 20. The method as claimed in claim 14, wherein the silver ion content in the zeolite is from 0.3% to 40% and the zinc ion content is from 1% to 15% as measured by the weight percentage of silver and zinc, respectively, in the aluminosilicate dried at 110.degree.C. 21. The method as claimed in claim 13, wherein the aluminosilicate having silver and zinc ions is administered at a dosage between 100 mg/day/adult and 10,000 mg/day/adult. 22. The method as claimed in claim 14, wherein the zeolite having silver and zinc ions is administered at a dosage between 100 mg/day/adult and 10,000 mg/day/adult. -------------------------------------------------------------------------------- |
| PATENT DESCRIPTION |
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a pharmaceutical composition for preventing and/or curing digestive disorders such as digestive ulcers, gastritis, etc. 2. Description of the Related Art It is said that digestive disorders such as typically gastric ulcers are so-called national diseases much seen in Japan, and the rate of the diseases in Japan is higher than that in other countries. Accordingly, various medicines for such digestive disorders have heretofore been developed and put into practical use. At present, however, better medicines for digestive disorders are desired. SUMMARY OF THE INVENTION The object of the present invention is to provide a pharmaceutical composition for preventing and/or curing digestive disorders such as digestive ulcers, gastritis, etc. In the situation as above, we, the present inventors have assiduously studied and have found that aluminosilicates having silver and zinc ions are effective for preventing and/or curing digestive disorders. In Japanese Patent Laid-Open No.244029/1992, described is an antimicrobial endermic preparation for external application which comprises, as the active ingredient, an aluminosilicate having silver and zinc ions. However, this has no relation to the potency of preventing and/or curing digestive disorders. Based on our finding as above, we, the inventors have completed the present invention. Specifically, the invention provides a pharmaceutical composition for preventing and/or curing digestive disorders, which is characterized in that it contains, as the active ingredient, an aluminosilicate having silver and zinc ions. Preferably, the aluminosilicate in the pharmaceutical composition is zeolite. Also preferably, the pharmaceutical composition is for preventing and/or curing digestive ulcers or gastritis. According to the invention, there is provided such a pharmaceutical composition for preventing and/or curing digestive disorders such as digestive ulcers, gastritis, etc. The pharmaceutical composition contains, as the active ingredient, an aluminosilicate having silver and zinc ions, and it has an excellent effect for protecting gastric mucous membrane and an excellent effect of promoting the curing of a gastric ulcer. DETAILED DESCRIPTION OF THE INVENTION The pharmaceutical composition of the invention for preventing and/or curing digestive disorders contains, as the active ingredient, an aluminosilicate having silver and zinc ions. The digestive disorders to which the invention is directed include, for example, digestive ulcers such as an esophageal ulcer, a gastric ulcer and a duodenal ulcer, and also esophagitis, gastritis, enteritis and enterogastric intestinal hemorrhage. Of those, the pharmaceutical composition of the invention is especially effective for curing a gastric ulcer, a duodenal ulcer and gastritis. The aluminosilicate for use in the invention may be any of a crystalline aluminosilicate generally referred to as zeolite, or an amorphous aluminosilicate. Zeolite for use herein may be any of natural zeolite or synthetic zeolite, including, for example, A-type zeolite, X-type zeolite, Y-type zeolite, T-type zeolite, sodalite, mordenite, analcime, clinobutyrolite, chabazite, erionite, etc. Preferably, the aluminosilicate has an average particle diameter falling between 0.5 .mu.m and 20 .mu.m for its better dispersibility. Regarding the amount of the silver and zinc ions in the aluminosilicate, it is desirable that the silver ions account for from 0.3% to 40% and the zinc ions for from 1% to 15% for ensuring long-lasting potency and stability of the pharmaceutical composition. The percentage, %, referred to herein is meant to indicate weight percentage of silver and zinc in the aluminosilicate dried at 110.degree. C. The aluminosilicate having silver and zinc ions for use in the invention can be formulated, for example, according to the method described in the above-mentioned Japanese Patent Laid-Open No. 244029/1992. Along with additives thereto, such as vehicle, binder, disintegrator, solubilizer, etc., the aluminosilicate having silver and zinc ions can be formulated in any known manner into oral preparations such as tablets, capsules, powders, granules, liquids for internal application, etc. The oral dose of the aluminosilicate having silver and zinc ions may be appropriately determined, depending on the condition of the patient who takes it. In general, it may fall between 100 mg/day/adult and 10000 mg/day/adult. |
| PATENT EXAMPLES | available on request |
| PATENT PHOTOCOPY | available on request |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |